The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medibank (MPL) CEO Craig Drummond is stepping down from his role on June 30, marking the end of five years with the company
  • Before he departs, Drummond says the company will continue its focus on preventative healthcare, short stay programs, clinical homecare and access to virtual care
  • Medibank Chairman Mike Wilkins has praised Drummond for his tenure saying he’s leaving the company in a stronger position
  • Medibank Private shares are trading 3.36 per cent lower at $2.79

Medibank (MPL) CEO Craig Drummond is stepping down from his role on June 30, marking the end of five years with the company.

Before his departure, Drummond says the company will continue to focus on working to deliver more preventative healthcare, short stay programs, clinical homecare and access to virtual care, such as telehealth.

”Pleasingly, Medibank is on a clear strategic path to grow the private health insurance business at a faster rate and continue the transformation into a broader healthcare company,” Drummond said.

“’I could not have been blessed with a more competent executive leadership team or supportive board,” he continued.

Medibank Chairman Mike Wilkins praised Drummond for his contribution.

“Craig has done a wonderful job in leading and transforming Medibank. He will leave the company in a much stronger position, on a clear strategic path, with a great team. This is the mark of outstanding leadership,” Mike said.

Investors appear to be wary about the management shake-up, with Medibank shares closing  3.36 per cent lower at $2.79.

MPL by the numbers
More From The Market Online
Molecules

Race Oncology approved for Phase I trial for chemotherapeutic treatments

Race Oncology Ltd has received approval to go ahead with its Phase I trial to assess…
US VA HQ

TrivarX flags US Veterans Affairs mental health trial – then halts trade for raise

TrivarX has halted shares ahead of a placement moments after just announcing a deal with the…
US flag

EZZ Life Sciences dips as company pushes manufacturing into US

EZZ Life Sciences (ASX:EZZ) fell -5% in early trades on Tuesday as the company flagged a…
The Market Online Video

Xanamem: Alzheimer’s breakthrough set for 2025, 2026

The search for an effective treatment for neurological conditions like Alzheimer’s disease remains one of the most urgent challenges in global healthcare.